Epidemiology and prognosis of synchronous and metachronous colon cancer metastases: A French population-based study

Digestive and Liver Disease

Volumn 46, Issue 9, 2014, Pages 854-858

  Ghiringhelli, Francois ^a,b   Hennequin, Audrey ^a   Drouillard, Antoine ^c,d   Lepage, CÔme ^b,c,d   Faivre, Jean ^b,c,d   Bouvier, Anne Marie ^b,c,d  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b Chu   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

^d Burgundy Digestive Tumours Registry   (France)

Author keywords

Colon cancer; Epidemiology; Metachronous metastasis; Registry; Synchronous metastasis

Indexed keywords

ANTINEOPLASTIC AGENT;

AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SURGERY; CANCER SURVIVAL; COLON CANCER; COLON METASTASIS; CONTROLLED STUDY; FEMALE; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; METACHRONOUS METASTASIS; METASTASIS; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PRIMARY TUMOR; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; SYNCHRONOUS METASTASIS; ADULT; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RISK; CAUSE OF DEATH; CLINICAL ASSESSMENT; EPIDEMIOLOGICAL DATA; FOLLOW UP; POPULATION; RISK ASSESSMENT; RISK FACTOR; COLONIC NEOPLASMS; HEALTH SURVEY; MORBIDITY; MULTIPLE CANCER; PROGNOSIS; RETROSPECTIVE STUDY; SECOND CANCER; SECONDARY; TRENDS;

AGED; COLONIC NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; MALE; MORBIDITY; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY; POPULATION SURVEILLANCE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84906316390     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.05.011     Document Type: Article

References (34)

1. Ferlay J., Shin H.R., Bray F., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 2010, 127:2893-2917.
2. Manfredi S., Bouvier A.M., Lepage C., et al. Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. British Journal of Surgery 2006, 93:1115-1122.
3. McArdle C. ABC of colorectal cancer: effectiveness of follow up. British Medical Journal 2000, 321:1332-1335.
4. Manfredi S., Lepage C., Hatem C., et al. Epidemiology and management of liver metastases from colorectal cancer. Annals of Surgery 2006, 244:254-259.
5. Venderbosch S., de Wilt J.H., Teerenstra S., et al. Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. Annals of Surgical Oncology 2011, 18:3252-3260.
6. Ko S., Jo H., Yun S., et al. Comparative analysis of radiofrequency ablation and resection for resectable colorectal liver metastases. World Journal of Gastroenterology 2014, 20:525-531.
7. Gallagher D.J., Kemeny N. Metastatic colorectal cancer: from improved survival to potential cure. Oncology 2010, 78:237-248.
8. Dawood O., Mahadevan A., Goodman K.A. Stereotactic body radiation therapy for liver metastases. European Journal of Cancer 2009, 45:2947-2959.
9. Milano M.T., Katz A.W., Zhang H., et al. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. International Journal of Radiation Oncology, Biology, Physics 2012, 83:878-886.
10. Van Cutsem E., Kohne C.H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. New England Journal of Medicine 2009, 360:1408-1417.
11. Saltz L.B., Clarke S., Diaz-Rubio E., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. Journal of Clinical Oncology 2008, 26:2013-2019.
12. Cummings L.C., Payes J.D., Cooper G.S. Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer 2007, 109:718-726.
13. Leporrier J., Maurel J., Chiche L., et al. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. British Journal of Surgery 2006, 93:465-474.
14. Bramhall S.R., Gur U., Coldham C., et al. Liver resection for colorectal metastases. Annals of the Royal College of Surgeons of England 2003, 85:334-339.
15. Fong Y., Fortner J., Sun R.L., et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Annals of Surgery 1999, 230:309-318. discussion 18-21.
16. Gayowski T.J., Iwatsuki S., Madariaga J.R., et al. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery 1994, 116:703-710. discussion 710-11.
17. Scheele J., Stang R., Altendorf-Hofmann A., et al. Resection of colorectal liver metastases. World Journal of Surgery 1995, 19:59-71.
18. Kato T., Yasui K., Hirai T., et al. Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Diseases of the Colon and Rectum 2003, 46:S22-S31.
19. Slesser A.A., Georgiou P., Brown G., et al. The tumour biology of synchronous and metachronous colorectal liver metastases: a systematic review. Clinical and Experimental Metastasis 2012.
20. De Jong K.P., Stellema R., Karrenbeld A., et al. Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology 1998, 28:971-979.
21. van der Wal G.E., Gouw A.S., Kamps J.A., et al. Angiogenesis in synchronous and metachronous colorectal liver metastases: the liver as a permissive soil. Annals of Surgery 2012, 255:86-94.
22. Mekenkamp L.J., Koopman M., Teerenstra S., et al. Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. British Journal of Cancer 2010, 103:159-164.
23. Kemeny N., Niedzwiecki D., Shurgot B., et al. Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment of liver involvement. Cancer 1989, 63:742-747.
24. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New England Journal of Medicine 2000, 343:905-914.
25. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of Clinical Oncology 2000, 18:2938-2947.
26. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. Journal of Clinical Oncology 2004, 22:229-237.
27. Colucci G., Gebbia V., Paoletti G., et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. Journal of Clinical Oncology 2005, 23:4866-4875.
28. Nordic Gastrointestinal Tumor Adjuvant Therapy Group Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. Journal of Clinical Oncology 1992, 10:904-911.
29. Graf W., Bergstrom R., Pahlman L., et al. Appraisal of a model for prediction of prognosis in advanced colorectal cancer. European Journal of Cancer 1994, 30A:453-457.
30. Freyer G., Rougier P., Bugat R., et al. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups. British Journal of Cancer 2000, 83:431-437.
31. Etienne-Grimaldi M.C., Formento J.L., Francoual M., et al. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clinical Cancer Research 2008, 14:4830-4835.
32. Ng W.W., Cheung Y.S., Wong J., et al. A preliminary analysis of combined liver resection with new chemotherapy for synchronous and metachronous colorectal liver metastasis. Asian Journal of Surgery 2009, 32:189-197.
33. Pantaleo M.A., Astolfi A., Nannini M., et al. Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. British Journal of Cancer 2008, 99:1729-1734.
34. Bockhorn M., Frilling A., Fruhauf N.R., et al. Survival of patients with synchronous and metachronous colorectal liver metastases - is there a difference?. Journal of Gastrointestinal Surgery 2008, 12:1399-1405.